As for the agents acting by enhancing neurotrophin action, xaliproden is a combined NGF potentiator and serotonin 5-HT1A receptor agonist that also reduces chemotherapy-induced peripheral sensory neuropathy but has yet to show efficacy in cognitive decline in AD. The gene discussed is NGF; the disease is Alzheimer disease.